In this study, we have demonstrated that VCX2 and other VCX genes are amenable to epigenetic induction by DNA methyltransferase and HDAC inhibitors in cancer cell lines and tumors and therefore may represent new targets for cancer immunotherapy (Figure 7). The gene discussed is VCX2; the disease is cancer.